Avoid common mistakes on your manuscript.
1 Correction to: Drugs (2021) 81:771–823 https://doi.org/10.1007/s40265-021-01507-z
The Gilteritinib package insert was cited as reference number 174 for values provided in the manuscript and tables [1]. Some of the specific values cited in the manuscript and tables are taken from non-PubMed indexed resources that were cited by the Gilteritinib FDA package insert. Specifically, the 9.76% rate of dry eye, 7.72% rate of retinal hemorrhage, and 8.13% rate of blurred vision were cited from NCT02421939 [2]. The 0.8% rate of eye edema is incorrect and should read 0.4% [3]. The 6.3% rate of dry eye, 3.2% rate of conjunctival hemorrhage, and 0.4% rate of eye edema were cited from deliberations of study results in Japan [3].
References
Pharma A. Highlights of prescribing information Gilteritinib. [cited 2022 2/9/2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf.
Astellas Pharma Global Development I. A study of ASP2215 versus salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) with FMS-like tyrosine kinase (FLT3) mutation. 2022 [cited 2022 2/9/2022]. https://clinicaltrials.gov/ct2/show/results/NCT02421939?view=results.
Pharmaceutical Evaluation Division PSaEHB-MoH, Labour and Welfare. Report on the deliberation results. 2018 [cited 2022 2/9/2022]. https://www.pmda.go.jp/files/000228502.pdf.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fortes, B.H., Tailor, P.D. & Dalvin, L.A. Correction to: Ocular Toxicity of Targeted Anticancer Agents. Drugs 82, 355 (2022). https://doi.org/10.1007/s40265-022-01686-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-022-01686-3